Valuation: Alkermes plc

Market Cap 8.73B 7.64B 7.06B 6.58B 12.4B 826B 12.62B 84.64B 32.86B 407B 32.81B 32.08B 1,420B P/E 2026 *
-138x
P/E 2027 * 88.1x
Enterprise Value 9.69B 8.49B 7.83B 7.31B 13.77B 917B 14.01B 93.96B 36.48B 452B 36.42B 35.61B 1,576B EV / Sales 2026 *
5.35x
EV / Sales 2027 * 4.99x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.26%
1 week+9.00%
1 month+24.19%
3 months+48.18%
6 months+87.26%
Current year+87.26%
1 week 50.01
Extreme 50.01
55.28
1 month 40.62
Extreme 40.62
55.28
Current year 27
Extreme 27
55.28
1 year 25.16
Extreme 25.165
55.28
3 years 22.01
Extreme 22.01
55.28
5 years 21.24
Extreme 21.24
55.28
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-12Sell

Director

-2,000 0.0012%
06-04Sell

Compliance Officer

-2,034 0.0012%
06-01Fiscal year

Chief Technology Officer

19,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+9.00%+83.14%+67.40% 8.73B
+2.22%+5.56%-1.10%+5.36% 47.18B
-2.77%+10.48%+409.05%+600.11% 39.82B
-0.03%+12.81%+22.61%-14.04% 32.25B
-1.73%+3.20%+17.72%+59.83% 31.68B
-3.29%+7.98%+14.01%+29.96% 24.59B
+1.15%+11.79% - - 16.57B
-0.96%+11.85%+68.73%+120.51% 15.12B
-0.29%+2.00%+12.47%+17.38% 13.69B
-1.74%+4.34%+100.68%+93.25% 13.1B
Average -0.77%+7.49%+80.81%+108.86% 24.27B
Weighted average by Cap. -0.68%+7.42%+93.41%+133.52%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.46B 1.37B 2.57B 171B 2.62B 17.56B 6.82B 84.52B 6.81B 6.65B 294B 1.89B 1.66B 1.53B 1.43B 2.69B 179B 2.73B 18.34B 7.12B 88.27B 7.11B 6.95B 308B
Net income -62.35M -54.58M -50.38M -47M -88.55M -5.9B -90.13M -604M -235M -2.91B -234M -229M -10.14B 108M 94.63M 87.35M 81.48M 154M 10.22B 156M 1.05B 407M 5.04B 406M 397M 17.57B
Net Debt 961M 841M 777M 724M 1.37B 90.89B 1.39B 9.32B 3.62B 44.85B 3.61B 3.53B 156B 702M 614M 567M 529M 996M 66.33B 1.01B 6.8B 2.64B 32.73B 2.64B 2.58B 114B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
30/06/26 $52.40 -0.26% 2,958,468
29/06/26 $52.53 -4.63% 2,940,864
26/06/26 $55.08 +4.26% 7,563,601
25/06/26 $52.83 +4.72% 3,249,672
24/06/26 $50.45 +4.95% 3,726,629
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
52.40USD
Average target price
49.44USD
Spread / Average Target
-5.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock